New long-term follow-up results from two Phase 3 studies evaluating CAMZYOS (mavacamten), a first-in-class cardiac myosin inhibitor, in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) were recently announced by Bristol Myers Squibb.
New long-term follow-up results from two Phase 3 studies evaluating CAMZYOS (mavacamten), a first-in-class cardiac myosin inhibitor, in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) were recently announced by Bristol Myers Squibb.
Results from VALOR-HCM LTE demonstrated that with longer follow-up, CAMZYOS continued to reduce eligibility for invasive SRT at 56 weeks
EXPLORER-LTE data showed sustained improvements in LVOT.
Bristol-Myers Squibb (BMY) Reports Follow-Up Data from Two Phase 3 Studies of CAMZYOS Demonstrate Consistent and Durable Response streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Results of the 56-week VALOR-HCM trial provide new insight into the effects of mavacamten in patients with highly symptomatic obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.